The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)–Seropositive and At‐Risk HIV‐Seronegative Women
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and section of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 1×
“glabrata was documented in recipients of bone marrow and liver transplants after fluconazole prophylaxis [16, 17, 37, 38].”
BackgroundRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 1×
“Susceptibility was also categorized as susceptible for isolates with fluconazole MIC values <5 mg/mL, susceptible dose dependent for isolates with fluconazole MICs of 10 or 20 mg/mL, and resistant for isolates with fluconazole MIC of 40 mg/ mL (values of 40 mg/mL were equivalent to >40mg/mL) [34].”
BackgroundSangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322 · cited 2×
“Fluconazole, a broad-spectrum azole antifungal agent, is an effective treatment for mucosal candidiasis, although exposure to fluconazole may result in mucosal colonization with Candida species that are less susceptible to antifungals or to the development of resistance among normally susceptible strains [2, 3, 6, 16-…”
BackgroundWinston, D. J., Pakrasi, A., & Busuttil, R. W. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00003 · Cited by 261
Risk Factors for Vulvovaginal Candidiasis: A Case- Control Study among University Students
Geiger, A. M., & Foxman, B. (1996) · Epidemiology · doi:10.1097/00001648-199603000-00013 · Cited by 154
Cited by
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Self-citationPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Bitew, A., & Abebaw, Y. (2018) · BMC Women's Health · doi:10.1186/s12905-018-0607-z · Cited by 205
“krusei is increasing, especially in HIV-infected women [16].”
BackgroundAn Update on the Roles of Non-albicans Candida Species in Vulvovaginitis
Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018) · Journal of Fungi · doi:10.3390/jof4040121 · Cited by 182
Management of recurrent vulvovaginal candidiasis: Unresolved issues
Sobel, J. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0023-7 · Cited by 36
Self-citation
Metadata
- Authors
- Sobel, J. D., Ohmit, S. E., Schuman, P., Klein, R. S., Mayer, K., Duerr, A., Vazquez, J. A., Rompalo, A., & HIV Epidemiology Research Study (HERS) Group
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-01-15
- Volume
- 183
- Issue
- 2
- Pages
- 286-293
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2115801155
- Cited by
- 83
- References
- 5
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.